[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of ciclesonide aerosol in healthy subjects under fasting conditions

主要目的：健康受试者空腹状态下，经口吸入单次给药环索奈德气雾剂（受试制剂T，上海上药信谊药厂有限公司生产，规格：80μg/揿）与环索奈德气雾剂（参比制剂R，Covis Pharma Gmbh生产，商品名：Alvesco®，规格：80μg/揿）后，考察空腹条件下受试制剂与参比制剂在人体内的吸收速度和吸收程度，评价受试制剂与参比制剂是否具有生物等效性。次要目的：观察受试制剂环索奈德气雾剂和参比制剂环索奈德气雾剂（Alvesco®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the absorption rate and extent of the test preparation and the reference preparation in the human body after oral inhalation of a single dose of ciclesonide aerosol (test preparation T, produced by Shanghai SPH Xinyi Pharmaceutical Co., Ltd., specification: 80μg/press) and ciclesonide aerosol (reference preparation R, produced by Covis Pharma Gmbh, trade name: Alvesco®, specification: 80μg/press) in healthy subjects under fasting conditions, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation ciclesonide aerosol and the reference preparation ciclesonide aerosol (Alvesco®) in healthy subjects.

Start Date12 Dec 2023

Sponsor / Collaborator

Shanghai Sine Pharmaceutical Co. Ltd.

EUCTR2020-002208-37-DK / Unknown statusPhase 2IIT

The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov

Start Date29 Apr 2021

Sponsor / Collaborator-

NCT04920838 / RecruitingPhase 2/3IIT

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Coverage Africa is a nested study in the large Anticov platform trial that aims to generate data on new early treatment strategies for mild/moderate COVID-19 patients in resource-limited-settings to reduce the number progressing to severe forms requiring hospitalization, thereby relieving the burden on health care systems and contributing to "flattening the curve" in contexts where none pharmaceutical intervention such as quarantine are difficult to implement in large urban settings. Treating early when the virus is still present might also limit transmission. Coverage Africa will be conducted in Guinea and Burkina Faso.
The main objective is to conduct an open-label, multicenter, randomized, adaptive platform trial to test the safety and efficacy of several marketed products, including antiviral therapies versus control in mild/moderate of coronavirus disease 2019 (Covid-19) in resource-limited-settings.
The study aims to recruit 600 patients in both countries, one site in Guinea and two sites in Burkina Faso.
The current assessed treatments are now the association of Fluoxétine/Budésonide compared with a control arm: paracetamol.
The adaptive design trial will allow for the removal of drugs, or the addition of new study arms when new data becomes available. Data on the primary efficacy parameters and safety will be integrated with the primary endpoint based on an oxygen saturation percentage (SpO2) ≤ 93% or death within 14 days after randomization to treatment, including death for any reason.
Study will run until August 2022. However, with the proposed adaptive design, the study could also be interrupted for success earlier than planned with the identification of a treatment that significantly reduces hospitalization rate as evidence by results from the primary endpoint.

Start Date12 Apr 2021

Sponsor / Collaborator

ANRS, Emerging Infectious Diseases

[+4]

100 Clinical Results associated with Ciclesonide

100 Translational Medicine associated with Ciclesonide

100 Patents (Medical) associated with Ciclesonide

414

Literatures (Medical) associated with Ciclesonide

01 Oct 2024·Current pharmaceutical biotechnology

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects

Review

Author: Pedreira, Lorena ; Alves, Brenda ; Nascimento, Daniel ; Fonseca, Ananda ; Hodel, Katharine ; Medina, Caio ; de Souza, Monielly ; Barbosa, Islania ; Maciel, Carine ; Godoy, Ana Leonor ; Oliveira-Junior, Gessualdo

Abstract::

Important physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the prevalence, severity, and lethality of the disease. Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin. Similarly, these differences between healthy people and obese people can be correlated to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the absorption and distribution of the vaccine that will be lower than desired or can be linked to the inflammatory state in obese patients, which can influence the humoral immune response. Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.

01 Sep 2024·PLACENTA

Characterisation of ciclesonide metabolism in human placentae across gestation

Article

Author: Simmons, Rebecca A ; Meakin, Ashley S ; Lien, Yu-Chin ; Gatford, Kathryn L ; Morrison, Janna L ; Wiese, Michael D

INTRODUCTION:

Current clinical management of pregnancies at risk of preterm delivery includes maternal antenatal corticosteroid (ACS) treatment. ACS activate the glucocorticoid receptor (GR) in all fetal tissues, maturing the lungs at the cost of impaired brain development, creating a need for novel treatments. The prodrug ciclesonide (CIC) activates the GR only when converted to des-CIC by specific enzymes, including acetylcholinesterase (ACHE) and carboxylesterase 1 and 2 (CES1, CES2). Importantly, the human placenta expresses ACHE and CES, and could potentially produce des-CIC, resulting in systemic fetal exposure and GR activation in all fetal tissues. We therefore investigated CES gene expression and conversion of CIC to des-CIC in human placentae collected during the second trimester (Tri2), and at preterm and term birth.

METHODS:

Differential expression analysis was performed in Tri2 (n = 27), preterm (n = 34), and term (n = 40) placentae using the DESeq2 R-package. Conversion of CIC to des-CIC was measured in a subset of placenta samples (Tri2 n = 7, preterm n = 26, term n = 20) using functional assays.

RESULTS:

ACHE mRNA expression was higher in Tri2 male than preterm and term male placentae only, whereas CES1 mRNA expression was higher in Tri2 than preterm or term placentae of both sexes. Conversion of CIC to des-CIC did not differ between gestational ages.

DISCUSSION:

Conversion of CIC to des-CIC by the human placenta may preclude its use as a novel GR-agonist in threatened preterm birth. In vivo studies are required to confirm the extent to which placental activation occurs after maternal treatment.

01 Sep 2024·Chinese Journal of Chromatography

Simultaneous determination of 61 hormones in water by solid phase extraction-ultra performance liquid chromatography-tandem mass spectrometry

Article

Author: Ma, Ming ; Pan, Chun-Yan ; Xu, Hong-Dan ; Chen, Yue-Qin

Concerns over the emergence of steroid hormones as pollutants in water have grown. Steroid hormone compounds present challenges in the simultaneous detection of total residual hormones owing to their analogous structures and diverse types. In this study, we established a rapid and high-throughput continuous online method based on solid phase extraction (SPE) coupled with ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for the simultaneous determination of 61 hormone components, including 48 glucocorticoids, 1 mineralocorticoid, 4 androgens, and 8 progesterones, in water. Various SPE columns were investigated to assess their extraction efficiency for enriching and purifying target compounds in a large sample volume (1 L). An HC-C18 SPE column was selected because of its superior performance. Acetonitrile was used as a washing solution during SPE to ensure that the majority of the tested substances achieved recoveries exceeding 70% and effectively avoid interferences from water-soluble components. Various C8 and C18 columns were tested, and the optimal HPLC conditions for hormone retention were established. We systematically evaluated different UPLC columns and mobile phases, including methanol-water and acetonitrile-water systems with 0.1% formic acid added to the aqueous phase. The optimized UPLC conditions were as follows: BEH C₁₈ column (100 mm×2.1 mm, 1.7 μm); column temperature, 40 ℃; flow rate, 0.3 mL/min; injection volume, 5 μL; mobile phase A: 0.1% formic acid aqueous phase; mobile phase B: acetonitrile. Gradient elution was performed as follows: 0-0.5 min, 30%B; 0.5-15.0 min, 30%B-75%B; 15.0-18.0 min, 75%B-98%B; 18.0-19.0 min, 98%B; 19.0-19.1 min, 98%B-30%B; 19.1-20.0 min, 30%B. Both positive- and negative-ion modes were explored in the UPLC-MS/MS experiment to obtain the full scan of the parent ions, and positive mode was finally selected for electrospray ionization (ESI). Two product ions exhibiting strong signals and minimal interference were selected for quantitative and qualitative ion analyses, using an external standard method for quantification. MS/MS was performed in positive-ion (ESI⁺) mode with multiple reaction monitoring (MRM) scanning. The MS/MS parameters were as follows: atomizing gas pressure, 379 kPa; curtain air pressure, 241 kPa; spray voltage, 5500 V; desolvation temperature, 550 ℃; collision exit voltage (CXP), 13 V; intake voltage (EP), 10 V; and residence time of each ion pair, 0.5 ms. Other instrument settings, such as the collision energy and declustering voltage, were also optimized. The 61 hormones exhibited excellent linear relationships within their corresponding concentration ranges, with correlation coefficients greater than 0.99. The method detection limits (MDLs) were in the range of 0.05-1.50 ng/L. The average recoveries of the 61 hormones across three spiked levels ranged from 62.3% to 125.2%, with relative standard deviations (RSDs, n=6) of 1.1%-10.5%. Using this method, we successfully detected 10 hormone components (cortisone, fluticasone propionate, ciclesonide, betamethasone dipropionate, clobetasone butyrate, diflucortolone valerate, halobetasol propionate, isoflupredone, difluprednate, and hydroxyprogesterone caproate) in various surface water and groundwater samples collected from the Taihu Basin region. The SPE-UPLC-MS/MS method presented in this paper is simple, highly sensitivity, and exceptionally accurate. Thus, it exhibits promising potential for tracing targeted hormone residues in water and will be of great value in monitoring and ensuring water safety. Finally, a regional analysis was conducted on the hormone levels in water, and suggestions were made for the targeted treatment of hormone residues in future sewage treatment processes.

News (Medical) associated with Ciclesonide

12 May 2023

·www.drugs.com

Get Relief With the Most Common Asthma Medications

FRIDAY, May 12, 2023 -- Receiving a diagnosis of asthma may be frightening, but learning what the treatment options are can help alleviate the anxiety that comes with diagnosis. Depending on the severity, certain asthma medications may help you manage your symptoms. Here, experts break down the most common long-term and quick-acting medications for asthma, how they work and potential side effects. Long-term medications These drugs are ones the patient takes daily as a means of controlling asthma and preventing asthma attacks. These can be in pill form or used as inhalers. Bronchodilators: Long-acting beta-2 agonists (LABA) relax the muscle bands around your airway (bronchi), making it easier to get air in and mucus out. These medications for asthma are taken twice a day through an inhaler and last up to 12 hours, according to the Cleveland Clinic . LABA medications should be given with a corticosteroid. (See combination medications below.) The main side effects of LABA medications are nervous or shaky feelings, hyperactivity, overexcitement, increased heart rate, upset stomach and trouble sleeping. Salmeterol (Serevent) Formoterol (Foradil) Long-acting muscarinic antagonists (LAMA) also relax the muscle bands around your airway, the National Heart, Lung, and Blood Institute (NHLBI) says. This asthma medication is used if the steroid/LABA combination doesn’t give enough relief. Do not use this medication if you have glaucoma or are at risk of urinary retention. Tiotropium bromide (Respimat) Theophylline. While not used often, theophylline can be useful in relaxing the airways and preventing reactions to irritants. It is taken as a pill and used for mild asthma symptoms. You may need to have blood tests drawn on a regular basis to make sure the level of medication is correct, the Mayo Clinic says. Side effects are the same as the other bronchodilators, but may also include chest pain or discomfort, dizziness, fainting, increase in urine volume or seizures. Theophylline (Theo-24, Theo-Dur, Slo-Bid, and others) Corticosteroids: Corticosteroids are steroids that reduce inflammation in the airways, according to the NHLBI. They may be taken as a pill, although very few patients are on the pill for long term. It is frequently used in an inhaler, often combined with a LABA. Side effects from the inhaled form are thrush (a mouth infection) and a hoarse voice. Inhaled corticosteroids include: Fluticasone (Flovent HFA, Arnuity Ellipta, others) Budesonide (Pulmicort Flexhaler) Mometasone (Asmanex Twisthaler) Beclomethasone (Qvar RediHaler) Ciclesonide (Alvesco) Combination asthma medications (Corticosteroid and LABA): Fluticasone and salmeterol (Advair) Budesonide and formoterol (Symbicort) Fluticasone and Vilanterol (Breo) Leukotriene modifiers reduce swelling and help keep your airways open for up to 24 hours. According to Mayo Clinic, these medications block the effects of leukotrienes, immune system chemicals that cause asthma symptoms. Side effects are uncommon, but may include nausea, headache, tiredness or diarrhea. Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Quick-acting asthma medications These are a group of medications that are used when a patient has a flare-up or an asthma attack. Inhaled short-acting beta2-agonists (SABAs) open the airways so air can flow through them during an asthma attack. They start working within 15 to 20 minutes and continue to work for 4 to 6 hours, according to the Cleveland Clinic. Side effects can include tremors, rapid heartbeat, allergic reactions, muscle pain, worsening breathing, dry mouth, headache, sore throat or trouble sleeping. Inhaled forms of SABA medications include: Albuterol (Ventolin) Levalbuterol (Xopenex) Albuterol and ipratropium bromide combination (DuoNeb) Corticosteroids. Oral corticosteroids are usually prescribed for short-term use to help a patient overcome a flare-up. This type of medication quickly reduces swelling and inflammation in the airways. Side effects include: Cataracts, osteoporosis, weight gain, high blood sugar, increased risk of infections, thinning bones and fractures, thin skin, bruising and slower wound healing, mood swings, depression and aggressive behavior. Prednisone (Deltasone, Prednicot, and others ) Methylprednisolone (Medrol, Solu-Medrol, Depo-Medrol) Short-acting anticholinergic bronchodilators help open the airways quickly. This medicine may be less effective than SABAs, but it is an option for people who experience side effects with other medications, the Cleveland Clinic says. Side effects you may experience with these inhalers are dry throat, eyes and nose; unusual taste; nausea and vomiting; or temporary blurred vision if the medicine gets in your eyes. Ipratropium bromide (Atrovent) Tiotropium bromide (Spiriva Respimat) Corticosteroid reliever. In January 2023, the FDA approved Airsupra, which can be used as needed to prevent bronchoconstriction and asthma attacks. In a study conducted before the approval, the risk of severe asthma exacerbation was significantly lower with a fixed-dose combination of albuterol and budesonide than with as-needed use of albuterol alone. Most common side effects are headache, oral yeast infection, cough, and difficulty speaking. Airsupra (albuterol-budesonide) Posted May 2023

Drug Approval

01 Nov 2021

·www.biospace.com

AstraZeneca Purges Two Respiratory Medicines in Big Day for Covis

Bodo Marks/picture alliance via Getty AstraZeneca’s respiratory portfolio is a little lighter as the British-Swiss pharmaceutical behemoth announced the offloading of two chronic obstructive pulmonary disease (COPD drugs) to fellow Swiss player Covis Pharma Group for $270 million. The agreement, announced November 1, involves Eklira (marketed as Tudorza in the U.S.) and Duaklir (marketed as Brimica® in some countries). The acquisition of the medicines – which netted AstraZeneca $143 million in the geographies covered under the agreement – provides a significant boost to Covis’s respiratory portfolio. COPD was the third leading cause of death worldwide in 2019, so the need and market are certainly there. “This acquisition represents a highly strategic and synergistic transaction with AstraZeneca, enabling Covis to offer a full continuum of best-in-class therapies for allergic rhinitis, asthma and COPD,” said Covis Chief Executive Officer Michael Porter in a statement. “As a result of the acquisition, Covis is firmly placed as one of the top 10 respiratory companies in the world.” Under the terms of the agreement, Covis will pay AstraZeneca $270 million upon completion of the deal, which is expected to close in quick order prior to the end of Q4 2021. In addition, Covis will be responsible for ongoing development costs related to the medicines. Eklira is a long-acting muscarinic antagonist (LAMA), while Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist. Both are presented as a dry powder for inhalation and delivered through a breath-actuated multi-dose dry powder inhaler called Genuair (Pressair in the US). AstraZeneca CEO Pascal Soriot has made no secret of his intention to steer the company's R&D pipeline to a predominantly oncology focus, and Covis is a repeat partner. In 2018, AstraZeneca divested three Asthma and Rhinitis Drugs to Covis for $350 Million. In this instance, the large multinational sold rights to Alvesco (ciclesonide), which is intended to treat persistent asthma, and Omnaris and Zetonna (ciclesonide), which are aimed at treating nasal symptoms associated with rhinitis. In April, Covis announced disappointing results from a Phase III trial evaluating Alvesco in COVID-19. The results were deemed not statistically significant, though Dr. Michael Blaiss, MD, clinical professor at the Medical College of Georgia at Augusta University in Augusta, Georgia and a member of the steering committee for the trial said that “further studies may want to look at whether this treatment may prevent or lessen post-acute COVID-19 syndrome.” AstraZeneca also said the deal will enable a sharpening of its focus on priority medicines in the respiratory and immunology space. The company went on to state in its official press release that the agreement “will ensure continued patient access to these established medicines.” With European headquarters in Zug as well as Amsterdam, Covis is a global specialty pharma company that markets therapeutics for patients with life-threatening conditions and chronic illnesses including asthma, COPD and anemia. Featured Jobs on BioSpace

Acquisition

18 Apr 2021

·www.globenewswire.com

COVIS PHARMA GROUP Announces Top-line Safety and Efficacy

ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection. The primary endpoint of the study was time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, feeling feverish, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell, defined as symptom-free for a continuous period of ≥ 24 hours by Day 30. A sub-group analysis showed that time to alleviation of cough was the most improved symptom in the ciclesonide arm compared to the placebo arm by 6 days in 75% of the population. A relevant secondary efficacy endpoint reaching statistical significance (p=0.0301) was the 70% reduction observed in the ciclesonide arm versus 30% in the placebo arm of patients with subsequent emergency department visits or hospital admissions for reasons attributable to COVID-19 by Day 30. There were only a small number (n=10) of total events observed in this study. No new safety signals were identified with ciclesonide 320mcg twice daily for 30 days in the active comparator arm versus placebo. In addition, no new adverse events were reported after 60 days post treatment with ciclesonide. The study randomized 400 patients in a 1:1 ratio to ciclesonide versus placebo. The study demonstrated a treatment difference between ciclesonide (70.6%) and placebo (63.5%) in the percentage of patients with an improved time to alleviation of COVID-19 related symptoms, which was not statistically significant, with a p-value of 0.5502. “We are disappointed the results were not more positive, although there was a trend toward earlier cough cessation in the ciclesonide group. Further studies may want to look at whether this treatment may prevent or lessen post-acute COVID-19 syndrome,” said Michael Blaiss, MD, clinical professor at the Medical College of Georgia at Augusta University in Augusta, Georgia, a member of the steering committee for the trial. About AlvescoAlvesco (ciclesonide) Inhalation Aerosol is a glucocorticoid indicated for the long-term treatment of asthma as maintenance therapy in adults and adolescents 12 years of age and older in the U.S. and over 6 years of age in Canada. Alvesco Inhalation Aerosol is an inhaled glucocorticoid with a small particle size (1-2 μm) enabling it to reach areas of chronic inflammation in both the large and small airways. Alvesco is not indicated for the relief of acute bronchospasm. Alvesco is not indicated for children under 12 years of age in the U.S. or under the age of 6 in Canada. Canada Indication: ALVESCO is indicated for the prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older.Contraindications: United States of America Indication: ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adults and adolescents 12 years of age and older.Important Limitations of USE: Important Safety Information for Alvesco (ciclesonide) Inhalation Aerosol Contraindications Warnings & Precautions Please read Important Safety Information and Full Prescribing Information for the US and Canada PM. About Covis Covis, with global operations in Zug, Switzerland, is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at . Trademarks are the property of their respective owners. Media Contactinfo@covispharma.com

100 Deals associated with Ciclesonide

External Link

KEGG	Wiki	ATC	Drug Bank
D01703	Ciclesonide	R01AD13 R03BA08	DB01410

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Perennial	US	Covis Pharma Holdings BV	20 Oct 2006
Rhinitis, Allergic, Seasonal	US	Covis Pharma Holdings BV	20 Oct 2006
Asthma	AU	CHIESI Farmaceutici SpA	24 Feb 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	US	Covis Pharma Holdings BV	08 Jun 2020
Childhood asthma	Phase 3	BR	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	DE	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	HU	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	PL	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	PT	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	ZA	AstraZeneca PLC	01 Oct 2004
Rhinitis perennial	Phase 3	US	AstraZeneca PLC	01 Dec 2003
Seasonal rhinitis	Phase 3	US	AstraZeneca PLC	01 Dec 2003
Persistent asthma	Phase 3	-	Takeda Pharmaceutical Co., Ltd.	01 Dec 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04381364 (HALT COVID-19, Pubmed)	Phase 2	COVID-19	98	Inhaled ciclesonide 320 µg	mzqihmhjwm(hkoltbllgu) = pafxrjphqy ndpmmwenwj (lrmuavgvob )	-	22 Feb 2023
				ciclesonide (Standard care)	mzqihmhjwm(hkoltbllgu) = bdicvomlsx ndpmmwenwj (lrmuavgvob )
NCT04435795 (CONTAIN, CTgov)	Phase 2/3	COVID-19	215	Ciclesonide (Ciclesonide Inhaled and Nasal)	krjzjgkdnc(oionrkrgtr) = dxmcvgafke irwwxgkkkv (uijoryaflq, ejajfycmcd - wciudrfxfv) View more	-	29 Apr 2022
				Normal Saline intranasal and placebo inhaler (Placebo)	krjzjgkdnc(oionrkrgtr) = aofvzehwpy irwwxgkkkv (uijoryaflq, qnxourlkfi - zqavopbnxq) View more
NCT00458835 (BY9010/M1-422, CTgov)	Phase 4	Rhinitis, Allergic	30	Ciclesonide (Ciclesonide Nasal Spray)	fkpfysnucc(hblqibpfxh) = gzacxxruoy okrviditvm (xeafqvpiom, gsgaravzad - nepjjbjbgg) View more	-	02 Mar 2022
				Ciclesonide (Ciclesonide Nasal Aerosol)	fkpfysnucc(hblqibpfxh) = cwvjdwxxcv okrviditvm (xeafqvpiom, eylwqcsenm - keyxgqwrmj) View more
NCT04377711 (CTgov)	Phase 3	COVID-19	400	Ciclesonide (Group 1)	bsffhjzyyq(cgjjibfezd) = dvburusmjx jqaizenaqt (psytvldigb, vfctpkaehf - uymsmwuwei) View more	-	06 Jan 2022
				Placebo (Group 2)	bsffhjzyyq(cgjjibfezd) = uixfcnecqy jqaizenaqt (psytvldigb, wmxkaecuqz - mqxknxbbax) View more
NCT04377711 (Pubmed \| JAMA Intern Med) Manual	Phase 3	COVID-19	400	Ciclesonide	yovobjjuvk(dwanxlvadc) = nslaeknteo rwtoaokoxo (fwudopbpud, 14.0 - 21.0)	Negative	22 Nov 2021
				Placebo	yovobjjuvk(dwanxlvadc) = rxmryhhcjo rwtoaokoxo (fwudopbpud, 16.0 - 23.0)
NCT04435795 (CONTAIN, Pubmed \| JAMA)	Phase 2	COVID-19	203	Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)	lypqsnfozj(krxgjssfue) = btlnkoecrc kctnpwlqot (wcmidvqqvk )	Negative	02 Nov 2021
				Metered dose inhaler and nasal saline placebos	lypqsnfozj(krxgjssfue) = urpckxdmzo kctnpwlqot (wcmidvqqvk )
NCT04330586 (Pubmed \| J Clin Med) Manual	Phase 2	COVID-19	61	ciclesonide	nhsxdwyhzq(fgpfczkvqn) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. ypkcueroly (yjzbvrmmbu ) View more	Positive	12 Aug 2021
				standard care
NCT01455194 (CONTRAST, CTgov)	Phase 3	Asthma	520	Ciclesonide (Treatment Period: Ciclesonide 160 mcg)	qdpdeegwsa(ixxcqjbmoh) = jrpwrvibts izzpessxhs (bshxjlwvqx, xczizwfxiz - gwpncslqle) View more	-	25 Oct 2016
				Ciclesonide (Treatment Period: Ciclesonide 320 mcg)	qdpdeegwsa(ixxcqjbmoh) = loehktcgyh izzpessxhs (bshxjlwvqx, zudkiwgjbu - qmjrikpxeq) View more
NCT02155881 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	80	Ciclesonide (Ciclesonide 200 mcg)	djhlmjrihr(qrjxifxmgd) = qqpzdilovr fqglvlbtcu (wweydftcbs, ipvwkttzsa - nviajzoybk) View more	-	06 Oct 2016
				Ciclesonide Placebo (Placebo)	djhlmjrihr(qrjxifxmgd) = oyqhrhcxsx fqglvlbtcu (wweydftcbs, lpamfwavtf - nftebtchpd) View more
NCT00384189 (RAINBOW, CTgov)	Phase 3	Asthma	1,080	Placebo+salbutamol+Ciclesonide (Ciclesonide 40 µg)	zbtmdzenkh(tfgwrublsu) = yrrsprbgky cccelwjumc (atjlmwkskp, dptavxutfg - tditdtwfll) View more	-	16 Aug 2016
				Placebo+salbutamol+Ciclesonide (Ciclesonide 80 µg)	zbtmdzenkh(tfgwrublsu) = uaicldgawp cccelwjumc (atjlmwkskp, zvacrdyypt - yaugmqbrhb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis